• Company
  • Supply Chain
Vizient agreement with Greenly enhances greenhouse gas data collection solution for providers and suppliers
The launch of Climate Performance Solutions marks the expansion of Vizient’s portfolio of impact spend services to help providers and suppliers achieve their environmental, social and governance goals.
  • Company
Vizient announces new agreement with RWJBarnabas Health
The agreement includes access to Vizient’s industry-leading contract portfolio of medical devices, supplies and pharmaceuticals as well as analytics-enabled solutions to drive operational and clinical efficiencies.
  • Company
Vizient to Acquire Kaufman Hall, Expanding Advisory Expertise for Healthcare Industry
The planned acquisition brings together two of the industry’s most trusted advisors to help healthcare organizations deliver high-quality patient care to their communities.
  • Company
Vizient welcomes new customer Adventist Health for solutions in spend management
The agreement was effective in the last quarter of 2023 and reflects Vizient’s continued commitment to supporting providers in high-value care.
  • Supply Chain
Vizient examines pulsed field ablation, wearables for women’s cardiovascular health in latest Medical Device Tech Watch
New technologies present providers with the opportunity to improve care pathways and determine how to provide cost-effective care.
  • Company
Vizient’s corporate responsibility report highlights positive impacts on people, places and the planet
The report shows progress on Vizient’s environmental, social and governance performance as well as support for sustainability efforts in the healthcare industry.
  • Company
Vizient showcases Vizient Vulnerability Index™ on Capitol Hill
Vizient, Inc. showcased the Vizient Vulnerability Index™ at the Healthcare Innovation Expo on Capitol Hill, an event hosted by the Healthcare Leadership Council in collaboration with the Health Care Innovation Caucus.
  • Company
Vizient announces renewed agreement with University of California Health
The agreement includes access to Vizient’s industry-leading contract portfolio, participation in Vizient Member Networks and more.
  • Company
Vizient shares feedback with CMS in IPPS Proposed Rule comments
Vizient, Inc. offered comments to the Centers for Medicare and Medicaid Services on the FY 2025 Inpatient Prospective Payment System (IPPS) Proposed Rule.
  • Data & Analytics
Sg2 projects continued constraints for patient access to care
Sg2, a Vizient, Inc. company, released its 2024 Impact of Change®, projecting continued constraints on patient access to emergency department (ED) and inpatient (IP) care.
  • Company
Vizient announces new customer agreement with Kettering Health
The agreement for the Ohio-based healthcare provider will maximize cost savings and supply chain efficiencies through Vizient spend management services
  • Company
Vizient announces new and renewed provider customers for Q1 2024
The new and renewed agreements signify Vizient’s value in helping healthcare providers deliver quality care at optimal efficiency.
  • Company
Vizient Shares Feedback with CMS on Medicare Advantage Data
Today, Vizient, Inc. submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to its Request for Information (RFI) on Medicare Advantage (MA) data.
  • Operations & Quality
  • Data & Analytics
Vizient report finds behavioral health Medicaid patients under-treated compared to commercially insured patients
While the prevalence of behavioral health conditions was roughly the same in both groups, treatment and emergency department visits among patients in each group varied.
  • Company
Vizient hosts congressional briefing on Medicare Advantage
The briefing, attended by a standing-room only crowd, focused on the disruptions caused by Medicare Advantage organizations and how hospitals are navigating the myriad challenges to provide timely and seamless care to MA beneficiaries.
  • Operations & Quality
Vizient/AACN Nurse Residency Program announces integration of Maryland R³ curriculum
The collaboration elevates NRP’s support of newly licensed nurses transitioning from classroom to clinical practice to promote quality and safety and reduce turnover
  • Pharmacy
Vizient conducts first Insight: Cell, Gene, and Specialty Pharmacy Symposium
The inaugural symposium brought together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals to discuss the promise the rapidly expanding market of cell, gene and other advanced therapies.
  • Company
Fortune Media and Great Place To Work Name Vizient to ‘100 Best Companies to Work For’ in 2024
This is Vizient’s third time being named to this prestigious list. Earning a spot means that Vizient is one of the best companies to work for in the country.
  • Operations & Quality
Vizient task force releases recommendations for hospitals on preparing for an active shooter event
The recommendations focus on appropriate communication, secure access, management of critically ill patients who are unable to run, hide and fight, and include tactics for addressing post-event trauma.
  • Company
Vizient announces agreement with Loma Linda University Health to provide solutions in expense management, quality benchmarking
The agreement includes a suite of Vizient spend management tools and access to operational and clinical analytics.
  • Company
Vizient announces trends for providers to strategize in 2024
It’s a year for bold bets in payer strategy, ambulatory design, primary care access and technology adoption.
  • Company
Vizient closes out 2023 with 37 new and renewed customers in Q4
The agreements reflect the value Vizient brings for providers seeking the alignment of cost, quality and market performance.
  • Supply Chain
Vizient Now Accepting Applications for 2024 Innovative Technology Exchange
The event will take place Sept.18 in Las Vegas during the Vizient Connections Summit and the deadline to apply is April 9.
  • Pharmacy
  • Company
Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals
In addition, the anticipated expansion of gene therapies will increase provider spend even more.